DelveInsight’s Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Adeno-Associated Virus Vectors in Gene Therapy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Adeno-Associated Virus Vectors in Gene Therapy: Overview
Adeno-associated virus (AAV) was first discovered from laboratory adenovirus (AdV) preparations in the mid-1960s and found in human tissues soon after3. Driven by pure scientific curiosity and without realizing its tremendous potential as a human gene therapy platform, a few research groups embarked on a journey to understand basic AAV biology. During the first 15–20 years of AAV research, several important aspects of AAV were characterized, including its genome configuration and composition, DNA replication and transcription, infectious latency and virion assembly.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market
Some of the key facts of the Adeno-Associated Virus Vectors in Gene Therapy Market Report
- According to the market research study by DelveInsight, the worldwide Adeno-associated virus (AAV) vectors in gene therapy market is expected to grow by 2030 at a significant CAGR.
- Increasing incidence of hematological and genetic disorders in both developed and developing economies has been fueling the demand for new treatments such as Adeno-associated virus (AAV) sectors in gene therapy.
- The growth of this market is driven majorly by factors such as the rising incidence of cancer, rising demand for adjuvant therapy drugs and cancer relapses during cancer treatment.
Adeno-Associated Virus Vectors in Gene Therapy Market
Adeno-Associated Virus Vectors in Gene Therapy market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Adeno-Associated Virus Vectors in Gene Therapy in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Adeno-Associated Virus Vectors in Gene Therapy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Adeno-Associated Virus Vectors in Gene Therapy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Adeno-Associated Virus Vectors in Gene Therapy Market Insights
There are a number of treatments that can be effective in Adeno-Associated Virus Vectors in Gene Therapy, but still, there are many unmet needs. Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and it needs to be combined with effective dietary management. Therefore, in children with a neonatal-onset disease or in those with very poor metabolic control, liver transplantation is also considered. So, there is an immediate need for R&D activities for the development of novel therapies that can overcome the limitations of existing therapies.
Adeno-Associated Virus Vectors in Gene Therapy Treatment Market
Recent advances in the treatment of inborn errors of urea synthesis have significantly decreased mortality. The treatment of Adeno-Associated Virus Vectors in Gene Therapy consists of dietary management to limit ammonia production, in conjunction with medications and/or supplements that provide alternative pathways for the removal of ammonia from the bloodstream. The aim is to correct biochemical abnormalities and ensure adequate nutritional intake. Treatment involves compounds that increase the removal of nitrogen waste. These compounds convert nitrogen into products other than urea, which are then excreted; hence, the load on the urea cycle is reduced. The first compounds to be used were sodium benzoate and arginine. Later, phenylacetate was used, which has now been replaced by phenylbutyrate.
Adeno-Associated Virus Vectors in Gene Therapy Epidemiology
The epidemiology section covers insights about the historical and current Adeno-Associated Virus Vectors in Gene Therapy patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Adeno-Associated Virus Vectors in Gene Therapy Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adeno-Associated Virus Vectors in Gene Therapy market or expected to get launched in the market during the study period. The analysis covers Adeno-Associated Virus Vectors in Gene Therapy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Adeno-Associated Virus Vectors in Gene Therapy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Adeno-Associated Virus Vectors in Gene Therapy Companies includes-
- uniQure
- Neurophth biological tech
- MeiraGTx (Phase I/II)
- Neurophth biological tech, and others
Adeno-Associated Virus Vectors in Gene Therapy Drugs includes-
- NFS-05
- AAV CNGA3
- NFS-01
- Etranacogene dezaparvovec, and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/